Jak inhibitor; Possibility and mechanism as a new disease modifying anti-rheumatic drug

Japanese Journal of Clinical Immunology

Volumn 32, Issue 2, 2009, Pages 85-91

  Yamaoka, Kunihiro ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Jak inhibitor; Rheumatoid arthritis; Specificity

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AT 9283; AURORA A KINASE; AURORA B KINASE; AZ 01; AZ 960; CYT 348; CYT 387; INCB 18424; INTERLEUKIN 10; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; LESTAURTINIB; PLACEBO; PROTEIN BCL 2; PROTEIN KINASE TYK2; PS 020613; PS 608504; R 348; SB 1518; SGI 1252; STAT6 PROTEIN; TG 101348; UNCLASSIFIED DRUG; VX 509; XL 019;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; PHARMACOLOGICAL BLOCKING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; JANUS KINASES;

EID: 77953673416     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.32.85     Document Type: Review

References (15)

1. Changelian PS, Flanagan ME, Ball DJ, et. al.: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 302: 875-878, 2003.
2. Kremer J, Cohen-S, Wilkinson B, et al.: The oral Jak inhibitor CP690, 550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate alone. [abstract] Arthritis Rheum. 58(suppl):L13, 2008.
3. Korn T, Bettelli E, Gao W, et al.: IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 448:484-487, 2007.
4. Yamaoka K, Min B, Zhou YJ, et al.: Jak3 negatively regulates dendritic cell cytokine production and survival. Blood. 106: 3227-3233, 2005.
5. Krause A, Scaletta N, Ji JD, et al.: Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol. 169:6610-6616, 2002.
6. Frucht DM, Aringer M, Galon J, et al.: Stat4 is expressed in activated peripheral blood monocytes, dendritic cells and macrophages at sites of Th1-mediated inflammation. J Immunol. 164:4659-4664, 2000.
7. Muller-Lander U, Judex M, Ballhorn W, et al.: Activation of the IL-4 STAT pathway in rheumatoid synovium. J Immunol. 164:3894-3901, 2000.
8. Walker JG, Ahern MJ, Coleman M, et al.: Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 65: 149-156, 2006
9. Walker JG, Ahern MJ, Coleman M, et al.: Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 65: 1558-1564, 2006.
10. Pesu M., Laurence A., Kishore N., et al.: Therapeutic targeting of Janus kinases. Immunol Rev. 223: 132-142, 2008.
11. Karaman MW, Herrgard S, Treiber KD, et al.: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26: 127-132, 2008.
12. Kremer JM, Bloom BJ, Breedveld FC, et al.: A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690, 550 versus placebo in the treatment of active rheumatoid arthritis. [abstract] Arthritis Rheum. 54(suppl); S33, 2006.
13. Williams W, Scherle P, Shi J, et al.: A Randomized placebo-controlled study of INCB018424 a selective Janus kinase1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). [abstract] Arthritis Rheum. 58(suppl); S431, 2008.
14. van Gurp EA, Schoordijk-Verschoor W, Klepper M, et al.: The effect of the JAK inhibitor CP-690, 550 on peripheral immune parameters in stable kidney allograft patients. Transplantation. 87: 79-86, 2009.
15. Changelian PS, Moshinsky D, Kuhn CF, et al.: The specificity of JAK3 kinase inhibitors. Blood. 111: 2155-2157, 2008.